{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T19:14:11Z","timestamp":1776539651915,"version":"3.51.2"},"reference-count":50,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OPTH"],"DOI":"10.2147\/opth.s503060","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T14:20:13Z","timestamp":1738765213000},"page":"395-406","source":"Crossref","is-referenced-by-count":2,"title":["Human Factors Studies to Assess the Usability of the Faricimab Prefilled Syringe"],"prefix":"10.2147","volume":"Volume 19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1328-6314","authenticated-orcid":true,"given":"Mark","family":"Barakat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Kwong Jr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gelson","family":"Marcon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"O'Leary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Paris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petrick","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8464-2817","authenticated-orcid":true,"given":"Yannan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Graff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4103\/jovr.jovr_50_18","volume":"13","author":"Nikkhah","year":"2018","journal-title":"J Ophthalmic Vis Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12886-020-01554-2","volume":"20","author":"Finger","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","volume":"125","author":"Rao","year":"2018","journal-title":"Ophthalmology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","volume":"255","author":"Lanzetta","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2023.26074","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1192464","DOI":"10.3389\/fncel.2023.1192464","volume":"17","author":"Canonica","year":"2023","journal-title":"Front Cell Neurosci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.2147\/DDDT.S427416","volume":"17","author":"Panos","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"},{"key":"ref12","unstructured":"VABYSMO\u2122 (faricimab-svoa). [US Food & Drug Administration prescribing information]. Genentech, Inc. San Francisco, CA, USA, 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761235s000lbl.pdf. Accessed September 6, 2024."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"ref15","first-page":"428","volume":"62","author":"Khanani","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","volume":"131","author":"Tadayoni","year":"2024","journal-title":"Ophthalmology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"ref19","unstructured":"Vabysmo\u2122 (faricimab). [European Medicines Agency Summary of Product Characteristics]. F. Hoffmann-La Roche AG. Basel, Switzerland, 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vabysmo-epar-product-information_en.pdf. Accessed September 6, 2024."},{"key":"ref20","unstructured":"Chugai Pharmaceuticals [homepage on the Internet]. Chugai obtains regulatory approval for Vabysmo, the first bispecific antibody in ophthalmology, for neovascular age-related macular degeneration and diabetic macular edema; 2022. Available from: https:\/\/www.chugai-pharm.co.jp\/english\/news\/detail\/20220328160002_909.html. Accessed June 18, 2024."},{"key":"ref21","unstructured":"Chugai Pharmaceuticals [homepage on the Internet]. Chugai obtains regulatory approval for Vabysmo, the only bispecific antibody in the ophthalmology field, for additional indication of macular edema associated with retinal vein occlusion; 2024. Available from: https:\/\/www.chugai-pharm.co.jp\/english\/news\/detail\/20240326160000_1054.html. Accessed June 18, 2024."},{"key":"ref22","unstructured":"European Medicines Agency [homepage on the Internet]. European Commission approves Roche\u2019s Vabysmo for treatment of retinal vein occlusion (RVO); 2024. Available from: https:\/\/www.roche.com\/media\/releases\/med-cor-2024-07-30. Accessed August 12, 2024."},{"key":"ref23","unstructured":"Genentech [homepage on the Internet]. FDA approves Genentech\u2019s Vabysmo for the treatment of retinal vein occlusion (RVO); 2023. Available from: https:\/\/www.gene.com\/media\/press-releases\/15009\/2023-10-26\/fda-approves-genentechs-vabysmo-for-the-. Accessed September 6, 2024."},{"key":"ref24","unstructured":"Ali F, Tabano D, Garmo V, et al. Two-year real-world clinical outcomes update with faricimab in patients with neovascular age-related macular degeneration in the USA: the FARETINA-AMD study. Hawaiian Eye and Retina meeting; 2025; Kauai, HI, USA January 18\u201324, 2025."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s40123-024-01002-0","volume":"13","author":"Uzzan","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1208\/s12249-021-01949-4","volume":"22","author":"Parenky","year":"2021","journal-title":"AAPS Pharm Sci Tech"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2147\/OPTH.S169044","volume":"13","author":"Sassalos","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"ref28","first-page":"10600280231212890","author":"Benhamou","year":"2023","journal-title":"Ann Pharmacother"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/24741264231191339","volume":"7","author":"Louis","year":"2023","journal-title":"J Vitreoretin Dis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ajo.2018.11.023","volume":"199","author":"Storey","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"ref31","unstructured":"Healio, Occular Surgery News [homepage on the Internet]. Significant investments will continue to advance retinal disease field; 2023. Available from: https:\/\/www.healio.com\/news\/ophthalmology\/20230915\/significant-investments-will-continue-to-advance-retinal-disease-field. Accessed August 1, 2024."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"100862","DOI":"10.1016\/j.preteyeres.2020.100862","volume":"80","author":"Melo","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"ref33","unstructured":"BEOVU\u00ae (brolucizumab-dbll). [US Food and Drug Administration Prescribing Information]. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761125s021lbl.pdf. Accessed September 6, 2024."},{"key":"ref34","unstructured":"EYLEA\u00ae (aflibercept). [US Food and Drug Administration Prescribing Information]. Regeneron Pharmaceuticals, Inc. Tarrytown, New York, USA, 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125387s084lbl.pdf. Accessed September 6, 2024."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"411","DOI":"10.5731\/pdajpst.2017.008342","volume":"72","author":"Antoszyk","year":"2018","journal-title":"PDA J Pharm Sci Technol"},{"key":"ref36","unstructured":"LUCENTIS\u00ae (ranibizumab injection). [US Food & Drug Administration prescribing information]. Genentech, Inc. San Francisco, CA, USA, 2024, Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125156s128lbl.pdf. Accessed September 6, 2024."},{"key":"ref37","unstructured":"Roche [homepage on the Internet]. FDA approves Roche\u2019s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss; 2024. Available from: https:\/\/www.roche.com\/media\/releases\/med-cor-2024-07-05. Accessed August 1, 2024."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1208\/s12249-011-9617-y","volume":"12","author":"Badkar","year":"2011","journal-title":"AAPS Pharm Sci Tech"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/jamaophthalmol.2017.1815","volume":"135","author":"Khurana","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1136\/bjophthalmol-2019-313823","volume":"104","author":"Melo","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1080\/02713683.2016.1276195","volume":"42","author":"Moisseiev","year":"2017","journal-title":"Curr Eye Res"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"18136","DOI":"10.1038\/s41598-022-23039-6","volume":"12","author":"Dingerkus","year":"2022","journal-title":"Sci Rep"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40942-022-00375-3","volume":"8","author":"Guest","year":"2022","journal-title":"Int J Retina Vitreous"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.clinthera.2013.05.020","volume":"35","author":"Aronson","year":"2013","journal-title":"Clin Ther"},{"key":"ref45","unstructured":"European Medicines Agency [homepage on the Internet]. Guideline on the quality requirements for drug-device combinations; 2019. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-quality-requirements-drug-device-combinations-first-version_en.pdf. Accessed August 1, 2024."},{"key":"ref46","unstructured":"US Food and Drug Administration [homepage on the Internet]. Applying Human Factors and Usability Engineering to Medical Devices. Guidance for Industry and Food and Drug Administration Staff; 2016. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/applying-human-factors-and-usability-engineering-medical-devices. Accessed June 18, 2024."},{"key":"ref47","unstructured":"The International Organization for Standardization [homepage on the Internet]. International Electrotechnical Commission 62366-1:2015(en) Medical devices - Part 1: application of usability engineering to medical devices; 201. Available from: https:\/\/www.iso.org\/obp\/ui\/en\/#iso:std:iec:62366:-1:ed-1:v1:en. Accessed July 25, 2024."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"529","DOI":"10.5301\/ejo.5000629","volume":"25","author":"Souied","year":"2015","journal-title":"Eur J Ophthalmol"},{"key":"ref49","first-page":"A5214","volume":"63","author":"Subhi","year":"2016","journal-title":"Dan Med J"},{"key":"ref50","first-page":"3124","volume":"65","author":"Ghanchi","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Clinical Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/99931","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/99931","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T14:20:21Z","timestamp":1738765221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/human-factors-studies-to-assess-the-usability-of-the-faricimab-prefill-peer-reviewed-fulltext-article-OPTH"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":50,"URL":"https:\/\/doi.org\/10.2147\/opth.s503060","relation":{},"ISSN":["1177-5483"],"issn-type":[{"value":"1177-5483","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}